Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.59 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | PTPRC | P08575 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7469130 | 0.84 | CYP19A1 (0.52) | CYP19A1CYP11B1CYP11B2SMN1; SMN2NPC1 | |
| SCHEMBL3606605 | 0.79 | PTPRC (0.57) | DHFRPTPRCPTPN1HPGDSMN1; SMN2 | |
| SCHEMBL29801747 | 0.79 | PTPRC (0.57) | DHFRPTPRCPTPN1HPGDSMN1; SMN2 | |
| SCHEMBL30167077 | 0.79 | PTPRC (0.57) | DHFRPTPRCPTPN1TNKS2HPGD | |
| SCHEMBL5979768 | 0.78 | CYP11B1 (0.62) | CYP19A1CYP11B1CYP11B2HPGDKDM4E | |
| SCHEMBL3010069 | 0.78 | CYP11B1 (0.65) | CYP19A1CYP11B1CYP11B2PDGFRBPDGFRA | |
| SCHEMBL23060791 | 0.76 | CYP19A1 (0.51) | CYP19A1CYP11B1CYP11B2SMN1; SMN2LMNA | |
| SCHEMBL3015714 | 0.76 | GSTP1 (0.61) | CYP19A1CYP11B1CYP11B2DHFRPTPRC | |
| SCHEMBL3331012 | 0.75 | CYP19A1 (0.52) | CYP19A1CYP11B1CYP11B2PTPRCPTPN1 | |
| SCHEMBL27979076 | 0.75 | PTPRC (0.57) | DHFRPTPRCPTPN1TNKS2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546392-B2 | 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases | UNIVERSITAET DES SAARLANDES (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | UNIVERSITAET DES SAARLANDES (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-2131826-A2 | 17BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008116920-A2 | 17BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | HSD17B1, HSD17B11, HSD17B2 | CYP19A1 15/4885CYP11B1 26/4885CYP11B2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.